| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2023 | 2483 | 4.320 |
Why?
|
| Medication Adherence | 5 | 2024 | 385 | 1.920 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2022 | 254 | 1.840 |
Why?
|
| Receptor, ErbB-2 | 9 | 2023 | 496 | 1.760 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2019 | 70 | 1.760 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2022 | 284 | 1.520 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 714 | 1.360 |
Why?
|
| Oncogene Proteins | 2 | 2021 | 140 | 1.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2015 | 98 | 1.130 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 1682 | 1.120 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 1119 | 1.070 |
Why?
|
| Receptors, Estrogen | 8 | 2020 | 789 | 0.960 |
Why?
|
| Thalidomide | 1 | 2024 | 36 | 0.920 |
Why?
|
| Social Class | 1 | 2024 | 181 | 0.860 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 170 | 0.810 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2022 | 6 | 0.800 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 6 | 0.800 |
Why?
|
| Estrogen Receptor alpha | 2 | 2022 | 449 | 0.720 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 15 | 0.710 |
Why?
|
| Prescription Drugs | 2 | 2019 | 52 | 0.710 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2005 | 85 | 0.670 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 74 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1250 | 0.620 |
Why?
|
| Cancer Survivors | 2 | 2018 | 187 | 0.610 |
Why?
|
| Quinolines | 1 | 2019 | 97 | 0.600 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 164 | 0.590 |
Why?
|
| Tamoxifen | 6 | 2022 | 363 | 0.550 |
Why?
|
| Female | 34 | 2024 | 65361 | 0.540 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 3299 | 0.540 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 267 | 0.530 |
Why?
|
| Estrogen Antagonists | 2 | 2018 | 103 | 0.530 |
Why?
|
| Mucositis | 1 | 2015 | 18 | 0.510 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 13 | 0.510 |
Why?
|
| Palliative Care | 1 | 2019 | 429 | 0.500 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2005 | 112 | 0.490 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 75 | 0.480 |
Why?
|
| Glutamine | 1 | 2015 | 195 | 0.470 |
Why?
|
| Quinazolines | 3 | 2015 | 175 | 0.450 |
Why?
|
| Thiazolidinediones | 2 | 2005 | 80 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2013 | 29 | 0.440 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 4 | 0.440 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2013 | 38 | 0.440 |
Why?
|
| Humans | 40 | 2024 | 122971 | 0.430 |
Why?
|
| Drug Eruptions | 1 | 2013 | 33 | 0.420 |
Why?
|
| Cytotoxins | 1 | 2012 | 21 | 0.410 |
Why?
|
| Furans | 1 | 2012 | 27 | 0.400 |
Why?
|
| Ketones | 1 | 2012 | 25 | 0.400 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 1586 | 0.400 |
Why?
|
| RANK Ligand | 1 | 2012 | 49 | 0.390 |
Why?
|
| Heterografts | 4 | 2022 | 183 | 0.380 |
Why?
|
| Cell Proliferation | 5 | 2022 | 2321 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 1193 | 0.360 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6343 | 0.350 |
Why?
|
| Estradiol | 4 | 2022 | 534 | 0.330 |
Why?
|
| Neoplasms | 2 | 2015 | 2751 | 0.330 |
Why?
|
| Aged | 10 | 2024 | 18998 | 0.330 |
Why?
|
| Mice | 11 | 2022 | 17647 | 0.330 |
Why?
|
| Obesity | 3 | 2023 | 2092 | 0.320 |
Why?
|
| Epothilones | 1 | 2008 | 2 | 0.320 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 10 | 0.320 |
Why?
|
| Estrogens | 3 | 2022 | 507 | 0.310 |
Why?
|
| Animals | 15 | 2022 | 33923 | 0.310 |
Why?
|
| Cell Membrane | 3 | 2005 | 460 | 0.300 |
Why?
|
| Middle Aged | 11 | 2024 | 25885 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 366 | 0.300 |
Why?
|
| Microtubules | 1 | 2008 | 197 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 428 | 0.290 |
Why?
|
| Postmenopause | 3 | 2023 | 124 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 321 | 0.270 |
Why?
|
| Transplantation, Autologous | 3 | 2013 | 300 | 0.260 |
Why?
|
| Adult | 9 | 2024 | 28944 | 0.260 |
Why?
|
| Administration, Oral | 2 | 2020 | 670 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 1021 | 0.260 |
Why?
|
| Dopamine | 2 | 2004 | 275 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2024 | 15934 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 1885 | 0.250 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2005 | 19 | 0.250 |
Why?
|
| Signal Transduction | 7 | 2021 | 4524 | 0.240 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 543 | 0.240 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 1222 | 0.230 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2004 | 27 | 0.230 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2004 | 98 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 710 | 0.220 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 654 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2019 | 12083 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 53 | 0.210 |
Why?
|
| Immunologic Factors | 1 | 2024 | 179 | 0.210 |
Why?
|
| Medicare | 2 | 2023 | 423 | 0.210 |
Why?
|
| Mice, Nude | 2 | 2021 | 697 | 0.200 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2021 | 16 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 54 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 251 | 0.190 |
Why?
|
| G1 Phase | 1 | 2021 | 67 | 0.190 |
Why?
|
| Hyaluronan Receptors | 2 | 2018 | 66 | 0.180 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 664 | 0.180 |
Why?
|
| Metformin | 1 | 2022 | 146 | 0.180 |
Why?
|
| Mastectomy | 1 | 2020 | 62 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 880 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2019 | 572 | 0.170 |
Why?
|
| Transcriptome | 2 | 2016 | 909 | 0.170 |
Why?
|
| Cancer Pain | 1 | 2019 | 24 | 0.160 |
Why?
|
| Polypharmacy | 1 | 2019 | 40 | 0.160 |
Why?
|
| Keratins | 1 | 2019 | 55 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 106 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.160 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 91 | 0.160 |
Why?
|
| Rats | 4 | 2008 | 3665 | 0.160 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 21 | 0.160 |
Why?
|
| Male | 9 | 2024 | 59957 | 0.160 |
Why?
|
| Breast | 1 | 2020 | 214 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 98 | 0.160 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 865 | 0.160 |
Why?
|
| Purines | 1 | 2018 | 107 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2018 | 53 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2021 | 335 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 67 | 0.150 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 372 | 0.150 |
Why?
|
| Cell Separation | 1 | 2019 | 240 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 353 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 404 | 0.150 |
Why?
|
| Indoles | 1 | 2018 | 182 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 171 | 0.150 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 660 | 0.150 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4308 | 0.140 |
Why?
|
| Neutropenia | 2 | 2009 | 202 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2020 | 756 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 351 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 286 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 325 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 49 | 0.140 |
Why?
|
| Atrophic Vaginitis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 107 | 0.130 |
Why?
|
| Texas | 1 | 2024 | 3542 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2016 | 209 | 0.130 |
Why?
|
| Pandemics | 1 | 2023 | 1104 | 0.130 |
Why?
|
| Taxoids | 1 | 2015 | 67 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 174 | 0.120 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 32 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 399 | 0.120 |
Why?
|
| Risk Factors | 4 | 2020 | 9950 | 0.120 |
Why?
|
| Rats, Zucker | 2 | 2005 | 41 | 0.120 |
Why?
|
| Colforsin | 2 | 2004 | 49 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 582 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2018 | 907 | 0.110 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 29 | 0.110 |
Why?
|
| Blood Component Removal | 1 | 2013 | 32 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 43 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 697 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 747 | 0.110 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 422 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2824 | 0.110 |
Why?
|
| Young Adult | 3 | 2019 | 8830 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1760 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 4503 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1216 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 1240 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 13 | 0.100 |
Why?
|
| Endocrine System | 1 | 2011 | 21 | 0.100 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 38 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 151 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 1381 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1431 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1034 | 0.090 |
Why?
|
| United States | 2 | 2023 | 10564 | 0.090 |
Why?
|
| Depression | 1 | 2019 | 1220 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 1164 | 0.090 |
Why?
|
| Leukopoiesis | 1 | 2009 | 3 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2005 | 1108 | 0.090 |
Why?
|
| Filgrastim | 1 | 2009 | 15 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 295 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2009 | 96 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1419 | 0.080 |
Why?
|
| California | 1 | 2009 | 128 | 0.080 |
Why?
|
| Ketoglutaric Acids | 1 | 2009 | 24 | 0.080 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2009 | 35 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2005 | 635 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 252 | 0.080 |
Why?
|
| Insulin | 2 | 2005 | 1196 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2011 | 702 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 1086 | 0.080 |
Why?
|
| Biological Assay | 1 | 2009 | 101 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 94 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1680 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 501 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 1287 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 3319 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 6020 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 770 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 129 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 323 | 0.070 |
Why?
|
| Time Factors | 3 | 2015 | 6216 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 567 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 222 | 0.070 |
Why?
|
| Survival Rate | 1 | 2011 | 1999 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1404 | 0.070 |
Why?
|
| CD24 Antigen | 2 | 2018 | 30 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 611 | 0.060 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1792 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2005 | 26 | 0.060 |
Why?
|
| Mutation | 1 | 2019 | 5794 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2004 | 25 | 0.060 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2004 | 26 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 12 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 198 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2004 | 153 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1529 | 0.060 |
Why?
|
| Microvilli | 1 | 2004 | 73 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 28 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 160 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2004 | 41 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 50 | 0.060 |
Why?
|
| Benzazepines | 1 | 2004 | 64 | 0.060 |
Why?
|
| Length of Stay | 1 | 2009 | 1281 | 0.060 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2004 | 39 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 88 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2004 | 247 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 175 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 1354 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 1389 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1248 | 0.050 |
Why?
|
| Sodium | 1 | 2004 | 290 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 369 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2004 | 1106 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 1217 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2005 | 1617 | 0.050 |
Why?
|
| Body Weight | 1 | 2005 | 966 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5025 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 2029 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2020 | 84 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1317 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 139 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 31 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 868 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 128 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 285 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 10 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 1009 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 240 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 37 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3257 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1491 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 426 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 213 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2013 | 27 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 667 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2013 | 52 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 346 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2799 | 0.030 |
Why?
|
| Stem Cells | 1 | 2018 | 713 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1473 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 817 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 129 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 465 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 993 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 122 | 0.020 |
Why?
|
| Adolescent | 1 | 2009 | 19043 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 286 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 308 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 238 | 0.020 |
Why?
|
| Terfenadine | 1 | 2010 | 2 | 0.020 |
Why?
|
| Quinidine | 1 | 2010 | 9 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 497 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1592 | 0.020 |
Why?
|
| Propanolamines | 1 | 2010 | 32 | 0.020 |
Why?
|
| Digoxin | 1 | 2010 | 43 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 7 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2009 | 16 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2009 | 68 | 0.020 |
Why?
|
| Succinic Acid | 1 | 2009 | 14 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2009 | 45 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 23 | 0.020 |
Why?
|
| Hydrazines | 1 | 2009 | 28 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 180 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1921 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 99 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 284 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1316 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 2952 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 799 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 2846 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2009 | 815 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2536 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2584 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4222 | 0.010 |
Why?
|